• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cybin Inc.

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    SC 13G 1 j1126240sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Cybin Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    23256X407

    (CUSIP Number)

     

    November 25, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     Page 1 of 10 pages 
     

     

    CUSIP No.  23256X407 13G Page 2 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,105,433

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,105,433 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,105,433 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5% 

    12

    type of reporting person

     

    OO 

     

     Page 2 of 10 pages 
     

     

    CUSIP No.  23256X407 13G Page 3 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,105,433

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,105,433 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,105,433 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5% 

    12

    type of reporting person

     

    IN 

     

     Page 3 of 10 pages 
     

     

    CUSIP No.  23256X407 13G Page 4 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,105,433

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,105,433 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,105,433 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5% 

    12

    type of reporting person

     

    PN 

     

     Page 4 of 10 pages 
     

     

    CUSIP No.  23256X407 13G Page 5 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    NEVADA 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    0 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0% 

    12

    type of reporting person

     

    CO 

     

     Page 5 of 10 pages 
     

     

    CUSIP No.  23256X407 13G Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    NEVADA 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0% 

    12

    type of reporting person

     

    CO 

     

     Page 6 of 10 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Cybin Inc., (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations that are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Shares, no par value (the “Common Shares”)

     

    Item 2(e).CUSIP Number 23256X407

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 1,105,433 of the Issuer’s Common Shares.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 1,105,433 of the Issuer’s Common Shares.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 7 of 10 pages 
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 1,105,433 of the Issuer’s Common Shares.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 20,001,406 Common Shares outstanding as of September 30, 2024, as set forth in Exhibit 99.1 attached to the Issuer’s Report of Foreign Private Issuer filed on Form 6-K that was filed with the Securities and Exchange Commission on November 13, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 5.5%
    Kevin Tang 5.5%
    Tang Capital Partners 5.5%
    Tang Capital Partners III 0.0%
    Tang Capital Partners IV 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 1,105,433 shares
    Kevin Tang 1,105,433 shares
    Tang Capital Partners 1,105,433 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 1,105,433 shares
    Kevin Tang 1,105,433 shares
    Tang Capital Partners 1,105,433 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     Page 8 of 10 pages 
     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 9 of 10 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: December 3, 2024  
         
    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
    TANG CAPITAL PARTNERS III, INC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         
    TANG CAPITAL PARTNERS IV, INC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         
    TANG CAPITAL MANAGEMENT, LLC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
    /s/ Kevin Tang  
    Kevin Tang  

      

     

    Page 10 of 10 pages

     

     

     

    Get the next $CYBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cybin Inc.

      SC 13G - CYBIN INC. (0001833141) (Subject)

      12/3/24 5:23:26 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 7:51:22 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 6:55:13 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    SEC Filings

    See more
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      6/3/25 5:18:12 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      5/22/25 4:20:09 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Cybin Inc.

      SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

      5/21/25 4:52:11 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

      - Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004

      6/3/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking place on Thursday, May 29, 2025, at 11:00 a.m. ET. The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include: The evolution of interventional psychiatry clinics and the importance of Cybin's partnership with Osmind. Progress of the CYB003 Phase 3 p

      5/22/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

      - U.S. Food and Drug Administration ("FDA") Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health - - Calls for FDA to be open to innovative treatments that show promise, even when they challenge traditional understanding of medicine - - CYB003 granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder ("MDD") - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent com

      5/20/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Cybin with a new price target

      Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

      3/13/25 7:34:44 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cybin with a new price target

      HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      11/22/21 6:24:49 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin downgraded by Maxim Group

      Maxim Group downgraded Cybin from Buy to Hold

      11/19/21 8:09:52 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

      - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

      4/23/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

      - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

      10/1/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or by proxy at the Meeting holding 453,195,063 common shares, representing 59.66% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are

      8/27/24 7:01:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Financials

    Live finance-specific insights

    See more
    • Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

      - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

      11/18/24 7:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

      - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

      11/14/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

      - Breakthrough Therapy Designation ("BTD") provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration ("FDA") guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder ("MDD") - - Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) - - Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline at four months -

      3/13/24 6:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care